Insilico Medicine ('Insilico'), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announces positive results from two Phase I studies in Australia and China of ISM5411, a novel gut-restricted and PHD specific Inhibitor designed and optimized with the support of Insilico's Chemistry42 commercially-available generative reinforcement learning platform, for Inflammatory Bowel Disease (IBD). "It is pleased to see the good safety and PK profiles of ISM5411, especially the low systemic exposure across all dose groups.These results are suggestive of the gut-restrictive property of ISM5411 and good potential for further clinical development," says Philip Ryan, MD, PhD, the Principal Investigator of ISM5411 Phase I study in Australia .
"As an advanced technology, AI has played important roles in drug discovery and clinical research. We are looking forward to following ISM5411 as it progresses into patient trials, where we hope to see clinical benefits stemming from this technology." "These positive Phase I results from the IBD program are highly encouraging, particularly in validating the gut-restricted pharmacokinetic profile," says Carol Satler, MD, PhD, Vice President for Clinical Development, Non-Oncology, Insilico Medicine, who will support the further development of ISM5411 for the treatment of IBD .
Given the limited therapeutic options and the challenges with current IBD treatments, we believe that new therapies will b.
